Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Radiation-induced effects and the immune system in cancer
Punit Kaur, Alexzander Asea
Frontiers in Oncology (2012) Vol. 2
Open Access | Times Cited: 212

Showing 1-25 of 212 citing articles:

Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta, Jeffrey W. Pollard
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 887-904
Open Access | Times Cited: 1580
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Eugene D. Kwon, Charles G. Drake, H. I. Scher, et al.
The Lancet Oncology (2014) Vol. 15, Iss. 7, pp. 700-712
Open Access | Times Cited: 1407
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
Susan F. Slovin, Celestia S. Higano, Omid Hamid, et al.
Annals of Oncology (2013) Vol. 24, Iss. 7, pp. 1813-1821
Open Access | Times Cited: 528
Combination strategies to maximize the benefits of cancer immunotherapy
Shaoming Zhu, Tian Zhang, Lei Zheng, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 433
Mechanisms regulating T-cell infiltration and activity in solid tumors
Evripidis Lanitis, Denarda Dangaj, Melita Irving, et al.
Annals of Oncology (2017) Vol. 28, pp. xii18-xii32
Open Access | Times Cited: 326
Localized Interleukin-12 for Cancer Immunotherapy
Khue G. Nguyen, Maura R. Vrabel, Siena M. Mantooth, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 323
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Jacob Stultz, Lawrence Fong
Prostate Cancer and Prostatic Diseases (2021) Vol. 24, Iss. 3, pp. 697-717
Open Access | Times Cited: 149
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Bhalchandra Mirlekar
SAGE Open Medicine (2022) Vol. 10
Open Access | Times Cited: 127
A review on lymphocyte radiosensitivity and its impact on radiotherapy
Harald Paganetti
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 43
Radiobiological basis of SBRT and SRS
Chang W. Song, Mi‐Sook Kim, L. Chinsoo Cho, et al.
International Journal of Clinical Oncology (2014) Vol. 19, Iss. 4, pp. 570-578
Closed Access | Times Cited: 172
State of the Art Treatment of Spinal Metastatic Disease
Ori Barzilai, Charles G. Fisher, Mark H. Bilsky
Neurosurgery (2017) Vol. 82, Iss. 6, pp. 757-769
Closed Access | Times Cited: 158
Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications
Masoud Najafi, Elahe Motevaseli, Alireza Shirazi, et al.
International Journal of Radiation Biology (2018) Vol. 94, Iss. 4, pp. 335-356
Closed Access | Times Cited: 151
Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery
Mi‐Sook Kim, Wonwoo Kim, In Hwan Park, et al.
Radiation Oncology Journal (2015) Vol. 33, Iss. 4, pp. 265-265
Open Access | Times Cited: 142
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al.
European Urology (2020) Vol. 78, Iss. 6, pp. 822-830
Open Access | Times Cited: 132
The Promise of Combining Radiation Therapy With Immunotherapy
Justin C. Jagodinsky, Paul M. Harari, Zachary S. Morris
International Journal of Radiation Oncology*Biology*Physics (2020) Vol. 108, Iss. 1, pp. 6-16
Open Access | Times Cited: 125
Roadmap: proton therapy physics and biology
Harald Paganetti, Chris Beltran, Stefan Both, et al.
Physics in Medicine and Biology (2020) Vol. 66, Iss. 5, pp. 05RM01-05RM01
Open Access | Times Cited: 123
Modulation of apoptosis by melatonin for improving cancer treatment efficiency: An updated review
Keywan Mortezaee, Masoud Najafi, Bagher Farhood, et al.
Life Sciences (2019) Vol. 228, pp. 228-241
Closed Access | Times Cited: 116
Macrophage biology plays a central role during ionizing radiation-elicited tumor response
Qiuji Wu, Awatef Allouch, Isabelle Martins, et al.
Biomedical Journal (2017) Vol. 40, Iss. 4, pp. 200-211
Open Access | Times Cited: 111
A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger?
Raffaella Marconi, Silvia Strolin, Gianluca Bossi, et al.
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0171559-e0171559
Open Access | Times Cited: 107
Damage-associated molecular patterns in tumor radiotherapy
Milad Ashrafizadeh, Bagher Farhood, Ahmed Eleojo Musa, et al.
International Immunopharmacology (2020) Vol. 86, pp. 106761-106761
Closed Access | Times Cited: 98
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M.L. Zegers, Nicolle H. Rekers, Dana H.F. Quaden, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 5, pp. 1151-1160
Open Access | Times Cited: 95
The role of dose rate in radiation cancer risk: evaluating the effect of dose rate at the molecular, cellular and tissue levels using key events in critical pathways following exposure to low LET radiation
Antone L. Brooks, David G. Hoel, R. Julian Preston
International Journal of Radiation Biology (2016) Vol. 92, Iss. 8, pp. 405-426
Open Access | Times Cited: 93
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura
Current Cancer Drug Targets (2018) Vol. 19, Iss. 8, pp. 595-630
Open Access | Times Cited: 93
Immune system in cancer radiotherapy: Resistance mechanisms and therapy perspectives
Keywan Mortezaee, Masoud Najafi
Critical Reviews in Oncology/Hematology (2020) Vol. 157, pp. 103180-103180
Closed Access | Times Cited: 92
Immunotherapy in Prostate Cancer
Emily K. Fay, Julie N. Graff
Cancers (2020) Vol. 12, Iss. 7, pp. 1752-1752
Open Access | Times Cited: 81
Page 1 - Next Page

Scroll to top